Pre-Market Review: VIVUS Inc., Sanofi, DENTSPLY Intl. Inc., and Acura Pharmaceuticals Inc.

    Pre-Market Review: VIVUS Inc., Sanofi, DENTSPLY Intl. Inc., and Acura
                             Pharmaceuticals Inc.

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

LONDON, October 16, 2013

LONDON, October 16, 2013 /PRNewswire/ --

The U.S. equity markets edged lower on Tuesday, October 15, 2013, with the S&P
500, the Dow Jones Industrial Average, and the NASDAQ Composite falling by
0.71%, 0.87%, and 0.56%, respectively. Shares in the healthcare sector
finished on a lower note as the broader market posted losses. The major movers
in the sector included Vivus Inc. (NASDAQ: VVUS) Sanofi (NYSE: SNY), DENTSPLY
International Inc. (NASDAQ: XRAY), and Acura Pharmaceuticals Inc. (NASDAQ:
ACUR). AAAResearchReports.com initiated preliminary technical research on
VVUS, SNY, XRAY, and ACUR. These free reports are accessible by signing today
at:

http://www.aaaresearchreports.com/register/ 

Vivus Inc.'s stock plummeted on Tuesday, tracking losses in the broader
market. The company's shares closed the day at$10.06, down 4.19%, after
oscillating between$9.99 and $10.50. A total of 2.97 million shares were
traded, which is above the daily average volume of 2.63 million. The company's
shares have lost 0.59% in the previous one month, compared to a gain of 0.60%
in the S&P 500 during the same period. Furthermore, Vivus Inc.'s stock is
trading below its 50-day and 200-day moving averages of $11.42 and $12.51,
respectively. The free technical analysis on VVUS is available by signing up
at:

http://www.AAAResearchReports.com/VVUS101613.pdf

On Tuesday, Sanofi's stock ended the session 1.62% lower than the previous
day's price of $50.10. The company's shares oscillated between $49.29 and
$49.68 before closing the day at $49.29. A total of 0.58 million shares were
traded, which is significantly below the daily average volume of 2.05 million.
The company's shares have gained 2.77% in the previous one month,
outperforming the S&P 500 which has gained 0.60% during the same period.
Further, Sanofi's stock is also trading below its 50-day and 200-day moving
averages of $50.17 and $50.86, respectively. Register now to download free
research on SNY at:

http://www.AAAResearchReports.com/SNY101613.pdf

DENTSPLY International Inc.'s stock declined 0.98% on Tuesday, reversing all
the gains from the previous trading session. The company's shares vacillated
between $44.15 and $44.63 before closing the day at $44.29. A total of 0.72
million shares were traded, which is marginally below the daily average volume
of 0.75 million. Despite Tuesday's pullback, the company's shares have
advanced 5.45% in the previous three months and 0.45% in the last three
trading sessions, compared to a gain of 0.92% and 0.32% in the S&P 500 during
the respective periods. Moreover, DENTSPLY International Inc.'s stock is
trading above its 50-day and 200-day moving averages of $43.19 and $42.11,
respectively. A free report on XRAY can be accessed by registering at:

http://www.AAAResearchReports.com/XRAY101613.pdf

On Tuesday, Acura Pharmaceuticals Inc.'s stock plummeted 3.95%, as the U.S.
equity market finished on a lower note. The company's shares ended the day at
$1.70 after fluctuating between $1.70 and $1.77 during the trading session. A
total of 0.49 million shares were traded, which is marginally above the daily
average volume of 0.46 million. Despite yesterday's losses, the company's
shares have surged 14.09% in the previous one month, outperforming the S&P 500
which has advanced 0.60% during the same period. Additionally, Acura
Pharmaceuticals Inc.'s stock is still trading above its 50-day moving average
of $1.68. Register with AAA Research Reports and download research on ACUR for
free at:

http://www.AAAResearchReports.com/ACUR101613.pdf

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE AAA Research Reports

Contact: Peter F. Jones; + 1 (646) 396-9126 (North America);
info@aaaresearchreports.com
 
Press spacebar to pause and continue. Press esc to stop.